Additionally, amplification of PRDM16 was found in leukemia (35), osteosarcoma (36), and gastric cancer (37), and reduced expression of PRM16 was observed in uterine leiomyosarcoma (38) and NSCLC (18, 39), which elucidated PRDM16 and also functions as an oncogene or TSG in several cancers as MECOM. The gene discussed is PRDM16; the disease is cancer.